These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34295548)

  • 1. Yes-activated protein promotes primary resistance of
    Su M; Zhan L; Zhang Y; Zhang J
    J Gastrointest Oncol; 2021 Jun; 12(3):953-963. PubMed ID: 34295548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
    Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
    Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.
    Wickenden JA; Jin H; Johnson M; Gillings AS; Newson C; Austin M; Chell SD; Balmanno K; Pritchard CA; Cook SJ
    Oncogene; 2008 Dec; 27(57):7150-61. PubMed ID: 18806830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
    Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
    Shimizu Y; Maruyama K; Suzuki M; Kawachi H; Low SK; Oh-Hara T; Takeuchi K; Fujita N; Nagayama S; Katayama R
    Cancer Lett; 2022 Sep; 543():215799. PubMed ID: 35724767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
    Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
    Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Grothey A; Fakih M; Tabernero J
    Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF
    Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
    Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
    Lin L; Sabnis AJ; Chan E; Olivas V; Cade L; Pazarentzos E; Asthana S; Neel D; Yan JJ; Lu X; Pham L; Wang MM; Karachaliou N; Cao MG; Manzano JL; Ramirez JL; Torres JM; Buttitta F; Rudin CM; Collisson EA; Algazi A; Robinson E; Osman I; Muñoz-Couselo E; Cortes J; Frederick DT; Cooper ZA; McMahon M; Marchetti A; Rosell R; Flaherty KT; Wargo JA; Bivona TG
    Nat Genet; 2015 Mar; 47(3):250-6. PubMed ID: 25665005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors.
    Xu T; Wang X; Wang Z; Deng T; Qi C; Liu D; Li Y; Ji C; Li J; Shen L
    Ther Adv Med Oncol; 2022; 14():17588359221105022. PubMed ID: 35747165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
    Oikonomou E; Koc M; Sourkova V; Andera L; Pintzas A
    PLoS One; 2011; 6(6):e21632. PubMed ID: 21738740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
    Corcoran RB; Dias-Santagata D; Bergethon K; Iafrate AJ; Settleman J; Engelman JA
    Sci Signal; 2010 Nov; 3(149):ra84. PubMed ID: 21098728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.